Drugmaker Pfizer and its German partner BioNTech submitted an application for emergency use authorization for a COVID-19 vaccine.
The companies say data shows the vaccine is 95% effective at preventing the disease. A second vaccine, from Moderna Inc., is showing similar results.
The U.S. has a contract to buy millions of the Pfizer-BioNTech doses once that vaccine is approved, with shots to be free of charge.
